Hexarelin vs Cartalax
Side-by-side comparison of key properties, dosing, and research.
- Summary
- Hexarelin is a potent synthetic GHRP and the strongest GH secretagogue in its class per unit dose. It also exhibits unique cardioprotective properties through direct binding to cardiac CD36 receptors, independent of GH release. Its potency is balanced by a tendency to desensitize GH release with prolonged use, making cycling important.
- Cartalax is a tetrapeptide bioregulator (Ala-Glu-Asp-Pro) developed by Professor Vladimir Khavinson for cartilage and connective tissue. It is tissue-specific for chondrocytes and cartilaginous structures, supporting cartilage matrix synthesis, slowing degenerative changes, and promoting joint longevity. It is used in the context of osteoarthritis, joint aging, and athletic cartilage preservation.
- Half-Life
- ~70 minutes
- Short (minutes); gene-regulatory effects are sustained
- Admin Route
- SubQ
- SubQ, Oral
- Research
- —
- —
- Typical Dose
- 100–200 mcg
- 10 mg per day
- Frequency
- 2–3 times daily
- Daily for 10–30 days
- Key Benefits
- Strongest GH pulse per mcg among GHRPs
- Unique direct cardioprotective effects via CD36
- Increased IGF-1 and muscle anabolism
- Accelerated recovery from training
- Bone density support
- Anti-aging via GH axis
- Potential cardiac rehabilitation benefits
- Supports cartilage matrix synthesis and maintenance
- May slow progression of osteoarthritic cartilage degradation
- Reduces chondrocyte apoptosis
- Promotes joint longevity in aging and high-impact sports
- Anti-aging effects on connective tissue
- Complementary to BPC-157 and TB-500 in joint recovery protocols
- Well tolerated in available human and animal research
- Side Effects
- Water retention
- Elevated cortisol
- Elevated prolactin (more pronounced than other GHRPs)
- Receptor desensitization with continuous use
- +1 more
- Generally well tolerated
- Mild injection site reactions
- No significant adverse events reported at standard doses
- Stacks With
- —
- —